Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 111, Issue 4, Pages 651-659
Publisher
Springer Nature
Online
2014-07-16
DOI
10.1038/bjc.2014.345
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial
- (2014) Sandro Pignata et al. LANCET ONCOLOGY
- Evaluation of Pegylated Liposomal Doxorubicin Dose on the Adverse Drug Event Profile and Outcomes in Treatment of Recurrent Endometrial Cancer
- (2013) Justin M. Julius et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- The Role of Pegylated Liposomal Doxorubicin in Ovarian Cancer: A Meta-Analysis of Randomized Clinical Trials
- (2013) J.-M. Gibson et al. ONCOLOGIST
- Treatment with the PARP-inhibitor PJ34 causes enhanced doxorubicin-mediated cell death in HeLa cells
- (2012) Natisha Magan et al. ANTI-CANCER DRUGS
- A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas
- (2012) S. Kummar et al. CLINICAL CANCER RESEARCH
- A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors
- (2012) A. Rajan et al. CLINICAL CANCER RESEARCH
- OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- (2012) Carol Aghajanian et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma
- (2012) J R Berenson et al. LEUKEMIA
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
- (2012) Jonathan Ledermann et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours
- (2011) O A Khan et al. BRITISH JOURNAL OF CANCER
- Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas
- (2011) S. Kummar et al. CANCER RESEARCH
- Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study
- (2011) Jens Samol et al. INVESTIGATIONAL NEW DRUGS
- Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients WithBRCA1orBRCA2Mutations and Recurrent Ovarian Cancer
- (2011) Stan B. Kaye et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
- (2011) Karen A Gelmon et al. LANCET ONCOLOGY
- Inhibition of poly (ADP-ribose) polymerase-1 enhances doxorubicin activity against liver cancer cells
- (2010) J.A. Muñoz-Gámez et al. CANCER LETTERS
- Histone H2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers
- (2010) C. E. Redon et al. CLINICAL CANCER RESEARCH
- Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses inBRCACarrier Ovarian Cancer Correlating With Platinum-Free Interval
- (2010) Peter C. Fong et al. JOURNAL OF CLINICAL ONCOLOGY
- Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse
- (2010) Eric Pujade-Lauraine et al. JOURNAL OF CLINICAL ONCOLOGY
- Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer
- (2010) Bradley J. Monk et al. JOURNAL OF CLINICAL ONCOLOGY
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
- (2010) Andrew Tutt et al. LANCET
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
- (2010) M William Audeh et al. LANCET
- PARP inhibitors in cancer therapy: Two modes of attack on the cancer cell widening the clinical applications
- (2009) Yvette Drew et al. DRUG RESISTANCE UPDATES
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started